Recombinant Mouse Fas Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-1994
Recombinant Mouse Fas Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-1994
Catalog No.: BLPSN-1994
Product Overview
| Tag | His |
| Host Species | Mouse |
| Accession | NP_032013.2 |
| Synonym | AI196731, APO1, APT1, CD95, lpr, TNFR6, Tnfrsf6 |
| Background | CD95 (APO-1/Fas) is an important inducer of the extrinsic apoptosis signaling pathway and therapy induced apoptosis of many tumor cells has been linked to the activity of CD95. is a prototype death receptor characterized by the presence of an 8 amino acid death domain in its cytoplasmic tail. This domain is essential for the recruitment of a number of signaling components upon activation by either agonistic anti-CD95 antibodies or cognate CD95 ligand that initiate apoptosis. The complex of proteins that forms upon triggering of CD95 is called the death-inducting signaling complex (DISC). The DISC consists of an adaptor protein and initiator caspases and is essential for induction of apoptosis. CD95 is also crucial for the negative selection of B cells within the germinal center (GC). Impairment of CD95-mediated apoptosis results in defective affinity maturation and the persistence of autoreactive B-cell clones. Changes in the expression of CD95 and/or its ligand CD95L are frequently found in human cancer. The downregulation or mutation of CD95 has been proposed as a mechanism by which cancer cells avoid destruction by the immune system through reduced apoptosis sensitivity. Thus, CD95 has therefore been viewed as a tumor suppressor. CD95 has been reported to be involved in the activation of NF-kappaB, MAPK3/ERK1, MAPK8/JNK, and the alternate pathways for CTL-mediated cytotoxicity. Accordingly, this protein is implicated in the pathogenesis of various malignancies and diseases of the immune system. The CD95/CD95L system was implicated in the etiology of inflammatory bowel disease (IBD) based, primarily, on the finding that CD95 is highly expressed in the intestinal epithelial cells and that epithelial apoptosis is increased in IBD. |
| Description | A DNA sequence encoding the extracellular domain of mouse FAS (NP_032013.2) (Met 1-Arg 169) was fused with a His tag at the C-terminus. |
| Source | HEK293 |
| Predicted N Terminal | Gln 22 |
| AA Sequence | Met 1-Arg 169 |
| Molecular Weight | The recombinant mouse FAS consists of 159 a.a. and has a predicted molecular mass of 18 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rmFAS is approximately 30-35 kDa due to glycosylation. |
| Purity | >98% as determined by SDS-PAGE |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Bioactivity | Measured by its ability to inhibit Fas Ligand induced apoptosis of Jurkat human acute T cell leukemia cells.The ED50 for this effect is typically 0.5-4ug/mL in the presence of 200ng/mL recombinant human Fas ligand. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. |
| Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
| Usage | For Research Use Only |
| Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
